Immunai

Immunai is a biotechnology company headquartered in New York, New York. Founded in 2019, Immunai currently employs 128 individuals and generates approximately $50 million in annual revenue. Immunai focuses on leveraging single-cell biology and artificial intelligence to comprehensively map and reprogram the immune system. Their efforts aim to drive groundbreaking therapeutic discoveries, expedite drug development processes, and ultimately enhance patient outcomes. Immunai distinguishes itself through its innovative approach of combining cutting-edge single-cell biology with powerful AI algorithms. This unique combination enables them to gain deeper insights into the complexities of the immune system, leading to more targeted and effective treatments. Interested parties can learn more about Immunai's groundbreaking research and therapeutic advancements by visiting their website at immunai.com.